In order to help patients living with hyperthyroidism, pharmaceutical company AbbVie has launched a new program for management called Good Morning Hypothyroidism. Millions of people in the United States are living with hyperthyroidism, a condition that is marked by an under-active thyroid.
The program is part of the www.OurMorningRoutine.com website, which is dedicated to helping patients network with one another and keep with a daily regimen to keep their hypothyroidism under control.
The site includes information about Synthroid, a manmade thyroid hormone that is one of the most commonly prescribed hyperthyroidism therapies, as well as coupons and other offers.
"Effectively managing hypothyroidism begins with understanding the disease," Dr. Michael Robinson, vice president of AbbVie's U.S. medical affairs, said. "Good Morning Hypothyroidism takes patient education to the next level by providing inspiration to not only learn, but remain motivated in the management of this life-long condition."
AbbVie is a global, research-based biopharmaceutical company that was formed in 2013 following separation from Abbott Labs.
